Media coverage about Acceleron Pharma (NASDAQ:XLRN) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.9674685814396 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Acceleron Pharma (NASDAQ XLRN) opened at $45.12 on Tuesday. Acceleron Pharma has a 1 year low of $23.07 and a 1 year high of $45.52. The firm has a market cap of $2,041.00, a price-to-earnings ratio of -17.42 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. During the same period in the prior year, the company earned ($0.55) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. analysts anticipate that Acceleron Pharma will post -2.65 EPS for the current fiscal year.
In related news, CFO Kevin F. Mclaughlin sold 4,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $42.42, for a total transaction of $169,680.00. Following the completion of the transaction, the chief financial officer now directly owns 45,300 shares of the company’s stock, valued at $1,921,626. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jean George sold 105,122 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the transaction, the director now directly owns 1,250 shares of the company’s stock, valued at $44,662.50. The disclosure for this sale can be found here. Insiders sold 135,021 shares of company stock valued at $5,034,598 over the last ninety days. Corporate insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Acceleron Pharma (XLRN) Getting Somewhat Positive Media Coverage, Analysis Finds” was first posted by BBNS and is the property of of BBNS. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://baseballnewssource.com/markets/acceleron-pharma-xlrn-receiving-somewhat-favorable-press-coverage-analysis-shows/1819950.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.